The Serum Institute of India (SII) has sought permission from the country’s drug regulator to conduct Phase-3 trial to evaluate the safety and immunogenicity of its COVID-19 vaccine Covovax as a booster dose in children aged two to 18 years, official sources said on Sunday. The Drugs Controller General of India (DCGI) had granted permission … Read more
Serum Institute of India CEO Adar Poonawalla on Friday warned against the return to the business-as-usual approach, saying we “can’t afford to put a price tag on the life of a citizen” as the pandemic is not behind us yet. The chief executive defended his call for lowering the vaccination gap to six months from … Read more
Vaccine major Serum Institute of India (SII) has appealed to the government to reduce the gap between the second and booster dose to six months from nine months at present to safeguard people against emerging COVID variants, according to its CEO Adar Poonawalla. Recalling that they could not meet the commitment of exporting vaccines in … Read more
A day before the Covid-19 booster shoot drive is rolled out, both major vaccine manufacturers went on to announce a massive price cut on their vaccines. The Covid-19 vaccines Covishied which is manufactured by the Serum Institute of India and Covaxin from Bharat Biotech earlier used to cost Rs 600 and Rs 1200 respectively, but … Read more
The COVID-19 Working Group of the NTAGI has recommended inclusion of the Serum Institute’s Covovax in the national vaccination programme for those aged 12 years and above, official sources said on Sunday. India’s drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group, … Read more
Poonawalla was speaking at a felicitation ceremony organised for him by the Mahratta Chamber of Commerce, Industries and Agriculture in Pune. Serum Institute of India’s chairman and MD Cyrus Poonawalla on Monday said his company works with the goal to sell vaccines at the price of a cup of tea and make them affordable for … Read more
Director, Government and Regulatory Affairs at the SII, Prakash Kumar Singh had put in an application to the DCGI on January 6 stating the Pune-based firm, in collaboration with Novavax Inc, is working on the development of a vaccine against omicron, an official source said, adding that the SII has obtained permission and licence to … Read more
Adar Poonawalla, chief executive officer, SII, tweeted on Friday and said the company had supplied 1.25 billion doses of Covishield in India and the government had enough data for this permission. Serum Institute of India (SII) has sought full approval for its Covid-19 vaccine, Covishield. SII has applied to the ministry of health and family … Read more
Jameel, the former head of the advisory group to the Indian SARS-COV-2 Genomics Consortia, said there is no data for the other combinations of vaccines as of now. Of the vaccines against COVID-19 approved in India, Covovax would be a better booster for those who were administered Covishield jabs than another dose of the same … Read more
On November 27, the Subject Expert Committee on COVID-19 had evaluated and deliberated on SII’s application and sought additional data from the company. An expert panel of the country’s central drug authority has recommended granting emergency use authorisation to Serum Institute of India’s COVID-19 vaccine ‘Covovax’ with certain conditions, official sources said on Monday. Prakash … Read more